The Food and Drug Administration (FDA) has approved the prescription to over-the-counter (OTC) switch for Perrigo’s Nasonex® 24hr Allergy (mometasone furoate monohydrate).

Nasonex is a corticosteroid indicated for the treatment of nasal symptoms of allergic rhinitis, nasal congestion associated with seasonal allergic rhinitis, nasal polyps, and the prophylaxis of seasonal allergic rhinitis in individuals. 

This is the first OTC formulation for Nasonex and will be available in full prescription strength. Each nasal spray delivers 50mcg of mometasone furoate monohydrate. The Company expects to have Nasonex 24HR Allergy available later this year.

Perrigo Executive VP & President, Consumer Self-Care Americas, Jim Dillard commented, “Successfully bringing Rx-to-OTC switches to market expands offerings available to consumers, enhances offerings for our retail partners and continues to differentiate Perrigo in the marketplace.” 

Reference

Perrigo announces US FDA approval for OTC use of Nasonex® 24hr Allergy. News release. Perrigo Company plc. Accessed March 18, 2022. https://www.prnewswire.com/news-releases/perrigo-announces-us-fda-approval-for-otc-use-of-nasonex-24hr-allergy-301505410.html